| News

Alentis raises 12.5 million Swiss francs

30.04.2019

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by BPI France, Schröder Adveq and the HTGF. Alentis develops therapeutics in advanced liver disease and cancer.

BaseLaunch, a healthcare accelerator operated by BaselArea.swiss, has been instrumental as an early stage financial and operational supporter in the formation of the company. Very important has also been SATT Conectus – the tech transfer office of all the players in public research in Alsace – by providing building and securing the IP portfolio.

According to a press release, Alentis was founded upon research work conducted by the group of Professor Thomas Baumert, the principal founder of the company. He works at the University of Strasbourg, the Inserm Institute for Viral and Liver Disease, the Laboratory of Excellence HepSYS and the Institut Hospitalo-Universitaire Strasbourg.

Alentis’ lead program is a humanized monoclonal antibody against a target that is fundamental to the pathology of liver fibrosis and hepatocellular carcinoma (HCC). Alentis’ research is powered by its proprietary drug discovery platform, which is based on a prognostic liver disease signature holding promise for further drug candidates in liver disease.

Andreas Wallnöfer, General Partner at BioMedPartners and board member of Alentis, describes Baumert’s research as “truly translational, with the result that a rapid transition from preclinical research to clinical development can be expected.

Alentis is led by Dr. Markus Ewert, who was previously CBO at Ablynx, headed global corporate development at GE Healthcare, and held various leadership positions at Novartis.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
Startups from the Basel Area ranked among the best
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Startups from the Basel Area ranked among the best

Startups from the Basel Area have been ranked highly in the TOP 100 Swiss Startup Award by Venturelab. The medtech...

Read More
Roche testing for coronavirus and flu simultaneously
Basel Area Business & Innovation, Innovation, Invest

Roche testing for coronavirus and flu simultaneously

The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that...

Read More
Hengrui Medicine sets up clinical research and development in Basel
Basel Area Business & Innovation, Innovation, Invest

Hengrui Medicine sets up clinical research and development in Basel

The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research...

Read More
Polyphor awarded exclusive licensing agreement for China
Basel Area Business & Innovation, Innovation, Invest

Polyphor awarded exclusive licensing agreement for China

The Basel Area-based company Polyphor has signed an exclusive licensing agreement with Fosun Pharma in China. Fosun Pharma will lead...

Read More
New label guarantees that data remains in Switzerland
Basel Area Business & Innovation, Innovation, Invest

New label guarantees that data remains in Switzerland

With the new “swiss hosting” label, the Basel-based company swiss made software Gmbh is guaranteeing that data will not be...

Read More
Coworking in the Basel Area – An Interview with Karin Crisanto
Basel Area Business & Innovation, Switzerland Innovation Park

Coworking in the Basel Area – An Interview with Karin Crisanto

Karin Crisanto recently joined Basel Area Business & Innovation as Head of Innovation Space and Infrastructure. She previously worked for...

Read More
Switzerland ranked in second place globally
Basel Area Business & Innovation, Invest

Switzerland ranked in second place globally

The chemical and pharmaceutical industry of Switzerland has been ranked number two in the world after the USA in terms...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.